Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS researchers and several international collaborators have been awarded funding from the Chan Zuckerberg Initiative to deliver an ancestrally diverse musculoskeletal atlas of healthy tissues.

The Chan Zuckerberg Initiative (CZI) announced $28 million in grants to support the inclusion of data from tissue samples from ancestrally diverse donors in the Human Cell Atlas (HCA). A total of 16 teams of researchers were successful – including single-cell biologists, tissue experts, computational biologists, and community-engaged researchers, who represent 31 different countries.

The "Ancestrally Inclusive Musculoskeletal Atlas Network" is receiving $2m in funding. The network is a global collaboration between multiple research institutes – the University of Oxford (UK), University of Bristol (UK), African Institute of Biomedical Science and Technology (Zimbabwe), University of Cambridge (UK), University of Southampton (UK) – with tissue collections spanning India, Zimbabwe, Turkey, The Gambia, Oman and Argentina.

The musculoskeletal system accounts for over one-third of adult body mass and is essential for locomotion, fine motor control and independence. A cellular 'road-map' of ancestrally inclusive healthy musculoskeletal tissues will provide fundamental metrics to define the diverse tissues of the musculoskeletal system.

Sarah Snelling, Associate Professor at NDORMS and chief investigator of the Ancestrally Inclusive Musculoskeletal Atlas Network says, "The HCA is a generational resource that, when combined with future disease datasets, will accelerate our understanding of disease pathogenesis, revolutionise drug discovery and pave the way for the cellular evaluation of therapeutic strategies. It is vital that such a public good is representative of, and available to all global populations.

"To create effective treatments and cures for all people, the biomedical community must work to increase representation in scientific research. About 80 percent of current genomic data is from people of European ancestry, which must change," said CZI Program Manager for Single-Cell Biology, Norbert Tavares. "The Ancestry Networks for the Human Cell Atlas will bring a much-needed perspective to single-cell research and provide key insights into how ancestry impacts healthy and disease states and has the potential to inform the path to treatments."

Mathew Baldwin, NIHR clinical lecturer, who is leading clinical aspects of the grant at NDORMS said, "Engagement of diverse populations for biospecimen donation is central to the delivery and future refinement of an ancestrally diverse cell atlas. Our local teams have well-established community relationships that will help ensure tissue donation is respectful of local culture and customs. As our network progressively expands we aim to facilitate the participation of donors across the full spectrum of under-represented communities." Local relationships with donors are particularly enhanced through the critical involvement of the SAMSON network (Gregson, Bristol; Ward, Southampton).

A flagship initiative of this network is to empower the data analysis within the low and middle-income countries where tissue is being collected. The goal is to "train the trainers", helping to establish global centres of genomic research within these ancestrally under-represented countries. Co-Principal Investigators Dr Adam Cribbs and Dr David Sims (Oxford), alongside Prof. Collen Masimirembwa at the African Institute of Biomedical Science and technology (AiBST), the leading biotechnology institute in Zimbabwe, will deliver a unique training platform focused on single-cell sequencing analysis. This will complement AIBST's already established two-year master's degree program in genomics, and will provide a platform for students and scientists to analyse single-cell data generated at each of the partner sites. Training will encompass the entire pipeline of single cell studies with Mathew Baldwin, alongside Vikas Khanduja (Cambridge) delivering clinical training and exploring clinical and infrastructure barriers to tissue donation, and Sarah Snelling and Christopher Buckley supporting laboratory and relevant musculoskeletal biology training across all sites.

Adam Cribbs, group leader in Systems Biology at NDORMS and computational lead for the project says, "Developing computational infrastructure and support across our network will be key to empowering the future generation of scientists. This will lead to an increased representation of ancestrally diverse samples within the Human Cell Atlas project."

The team from NDORMS is working alongside international Co-Principal Investigators:

David SimsVikas KhandujaCelia GregsonKate WardCollen Masimirembwa

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.